Clinical trial results reveal that a medication used to treat Alzheimer’s disease may also be an effective therapy for individuals addicted to opioids. The findings are published in The American Journal on Addictions.
The medication, called galantamine, is thought to have a dual mechanism of action—it increases levels of a chemical messenger called acetylcholine in the brain and also binds to nicotinic receptors, which play a role in addiction to nicotine and other substances.
Participants who took galantamine had fewer urine samples that were positive for opioids compared with those who took placebo, which corroborated with self-reported abstinence in those who took galantamine. Also, participants who used opioids during follow-up took longer to do so if they were in the galantamine group.
“My colleagues and I are excited about these preliminary findings, as they could point to new strategies for helping those with opioid use disorder. We hope to pursue this in future research,” said lead author Kathleen Carroll, PhD, of the Yale University School of Medicine.
Reference: Kathleen M. Carroll , et al. Double‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use. American Journal on Addictions (2019) DOI: https://doi.org/10.1111/ajad.12904
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.